Mainstream

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Post ContentalnyRead More

You might also be interested in reading Bitwise aims to offer prediction market ETFs for U.S. elections in 2026 and 2028.

February 14, 2025
In Mainstream